Rule 1: The presence of certain functional groups in a molecule may indicate its potential for causing adverse effects. For example, the presence of a carbonyl group (C=O) or a sulfhydryl group (SH) in a compound may increase its reactivity and make it more likely to interact with biological molecules and cause harm. Therefore, identifying these functional groups in a molecule could be a first step towards predicting its toxicity.
Rule 2: The size and shape of a molecule can also affect its ability to interact with other molecules and cause adverse effects. For instance, large and complex molecules may have a higher likelihood of interacting with multiple targets within cells, leading to more severe consequences. Therefore, analyzing the structure of a molecule using computational methods such as molecular modeling can provide valuable insights into its potential toxicity.
Rule 3: The chemical composition of a molecule can also play a role in determining its toxicity. For example, some elements such as metals or halogens may increase the reactivity of a molecule and enhance its ability to cause damage. Additionally, the presence of certain atoms or bonds may create sites of vulnerability where the molecule can react with biological molecules. Therefore, understanding the elemental composition and bonding patterns of a molecule can help identify its potential risks.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a benzene ring or a phenol group, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules such as C1=CC(=CC=C1O)O, CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O, C1=CC(=CC=C1SC(P(=O)(O)[O-])P(=O)(O)[O-])Cl.[Na+].[Na+], C(=NC(=N)N)(N)N, CCC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C, COC(=O)C(C1CCCCN1)C2=CC=CC=C2, C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl, CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC, C1CC1NC2=NC(=NC3=C2N=CN3[C@@H]4C[C@@H](C=C4)CO)N, CCS(=O)(=O)C(C(F)(F)F)(C(F)(F)F)CF, NCC(C(=O)N)NNC

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a similar functional group, it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). The presence of this group indicates that the molecule may interfere with the body's normal functioning of carbonic anhydrase enzymes, which are involved in regulating pH levels within cells. This interference can lead to changes in cell growth and division, which can contribute to the development of cancer.
Rule 2: If the molecule contains a nitro group (-NO2) attached to an aromatic ring, it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Nitro groups are known to be highly reactive and can interact with other molecules in the body, leading to cellular damage and inflammation. These types of reactions can contribute to the development of cancer by causing mutations in DNA and promoting the growth of abnormal cells.
Rule 3: If the molecule contains a halogen atom such as chlorine (Cl) or fluorine (F), it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Halogen atoms can alter the chemical properties of a molecule

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a benzene ring with a sulfonamide substituent (-SO2NH2), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure and properties:
Rule 1: If the molecule contains a bromine atom, it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). The presence of a bromine atom in a molecule often indicates that it has a high degree of reactivity, which could potentially lead to harmful interactions with other molecules or biological systems. However, this rule should be applied cautiously as there may be other factors that contribute to the toxicity of a molecule beyond the presence of a specific functional group or structural feature.
Rule 2: If the molecule contains a nitrogen atom bonded to a carbon atom through two single bonds instead of one double bond, it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This type of nitrogen atom is known as a primary amine, and it is often associated with increased reactivity and toxicity compared to other types of amines.
Rule 3: If the molecule contains a carbonyl group (a carbon-oxygen double bond) conjugated with another double bond, such as in the case of an enone or a dienone, it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Conjugated carbonyl groups can undergo nucleophilic addition reactions with other molecules, leading to the formation of toxic adducts or metabolites

================================

Based on these data points, here are three possible rules for predicting if a given molecule has potential side effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a fluorine atom bonded to a carbon atom in the position indicated by the SMILES string CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F, then it may have potential side effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps).
Rule 2: If the molecule contains a functional group represented by the SMILES string CCC(=O)NNC(=O)C(c2ccc(cc2)n2cnc3ccccc32)C(=O)Nc1ccc(cc1)nn1cnc2ccccc21, then it may have potential side effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps).
Rule 3: If the molecule contains a functional group represented by the SMILES string C#CC1=C(C(=O)NS(=O)(=O)C2=C(C=C(C=C2Br)Br)Br)SC(=O)N1C, then it may have potential side effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps).

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a similar functional group, it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). The presence of this group indicates that the molecule may interfere with the body's normal functioning of carbonic anhydrase enzymes, which are involved in regulating pH levels within cells. This interference can lead to changes in cell growth and division, which can contribute to the development of cancer.
Rule 2: If the molecule contains a nitro group (-NO2) attached to an aromatic ring, it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Nitro groups are known to be highly reactive and can interact with other molecules in the body, leading to cellular damage and inflammation. These types of reactions can contribute to the development of cancer by causing mutations in DNA and promoting the growth of abnormal cells.
Rule 3: If the molecule contains a halogen atom such as chlorine (Cl) or fluorine (F), it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Halogen atoms can alter the chemical properties of a molecule

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps):
Rule 1: If the molecule contains a nitro group (-NO2), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules numbered 7, 9, and 18 in the dataset.
Rule 2: If the molecule contains a sulfonyl group (-SO2R), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules numbered 10 and 11 in the dataset.
Rule 3: If the molecule contains a halogen atom such as chlorine or fluorine attached to a carbon atom, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules numbered 12 and 13 in the dataset.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps):
Rule 1: If a molecule contains the substructure "Cl" or "Br" attached to a benzene ring, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules C1, D1, E1, F1, G1, H1, I1, J1, K1, L1, M1, N1, O1, P1, Q1, R1, S1, T1, U1, V1, W1, X1, Y1, Z1, A2, B2, C2, D2, E2, F2, G2, H2, I2, J2, K2, L2, M2, N2, O2, P2, Q2, R2, S2, T2, U2, V2, W2, X2, Y2, Z2, AA2, AB2, AC2, AD2, AE2, AF2, AG2, AH2, AI2, AJ2, AK2, AL2, AM2, AN2, AO2, AP2, AQ2, AR2, AS2, AT2, AU2, AV2, AW2, AX2, AZ2

================================

Rule 1: The presence of certain functional groups in a molecule may indicate its potential for causing adverse effects. For example, the presence of nitro groups (-NO2) or sulfonamide groups (-SO2NH2) in a compound may increase its toxicity. Therefore, molecules containing these groups should be carefully evaluated for their safety profiles.
Rule 2: The size and shape of a molecule can also affect its ability to interact with biological targets and potentially cause adverse effects. Molecules with large, complex structures may have difficulty penetrating cell membranes and accessing target sites within cells. On the other hand, smaller molecules may be more likely to cross cellular barriers and exert toxic effects. Therefore, molecular weight and lipophilicity should be considered when evaluating the potential toxicity of a compound.
Rule 3: The chemical reactivity of a molecule can also play a role in determining its potential for causing adverse effects. Highly reactive compounds may undergo rapid metabolism or degradation in vivo, reducing their bioavailability and limiting their potential for causing harm. However, some highly reactive compounds may also exhibit potent biological activities and cause significant toxicity at low doses. Therefore, the stability and reactivity of a compound should be taken into account when assessing its potential risks.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a carbonyl group (-C=O), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules represented by SMILES strings CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)[O-])C, C1=NC2=C(N1COCCO)NC(=NC2=O)N, CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2, COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F, CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O.Cl, CCS(=O)(=O)C1=CC=C(C=C1)N, NCC

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a carbonyl group (C=O), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules #7, #8, #9, #10, #11, #12, #13, #14, #15, #16, #17, #18, #19, #20, #21, #22, #23, #24, #25, #26, #27, #28, #29, #30, #31, #32, #33, #34, #35, #36, #37, #38, #39, #40, #41, #42, #43, #44, #45, #46, #47, #48, #49, #50

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a benzene ring or a phenol group, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules such as C1=CC(=CC=C1O)O, CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O, C1=CC(=CC=C1SC(P(=O)(O)[O-])P(=O)(O)[O-])Cl.[Na+].[Na+], C(=NC(=N)N)(N)N, CCC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C, COC(=O)C(C1CCCCN1)C2=CC=CC=C2, C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl, CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC, C1CC1NC2=NC(=NC3=C2N=CN3[C@@H]4C[C@@H](C=C4)CO)N, CCS(=O)(=O)C(C(F)(F)F)(C(F)(F)F)CF, NCC(C(=O)N)NNC

================================

Rule 1: If the molecular structure contains a benzene ring or a heterocyclic aromatic system, then it may have potential carcinogenic effects. The presence of such structures in a compound increases its ability to bind to DNA and disrupt normal cellular processes leading to cancer. Therefore, compounds containing these structures should be avoided if possible.
Rule 2: If the molecular structure contains a nitro group (-NO2), then it may have potential mutagenic and carcinogenic effects. Nitro groups can interact with DNA and lead to mutations, which can result in various types of cancers. Therefore, compounds containing nitro groups should be used with caution.
Rule 3: If the molecular structure contains a sulfhydryl group (-SH), then it may have potential toxic effects on the body. Sulfhydryl groups can react with other molecules and form disulfides, which can damage cells and tissues. Therefore, compounds containing sulfhydryl groups should be used with caution.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps):
Rule 1: If the molecule contains the substructure "CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl" or "CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C" then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). These substructures contain the nitrogenous base cytosine which is known to have anti-neoplastic properties. However, further analysis would be required to confirm this hypothesis.
Rule 2: If the molecule contains the substructure "C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F" then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This substructure contains the fluorinated organic compound hexafluoropropene which is commonly used as a refrigerant and solvent but has also been shown to have anti-cancer properties. Further analysis would be required to determine its specific mechanism of action.
Rule 3: If the molecule contains the substructure "CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C" or "CCCCCCCCCCCCCCCOS(=O)(=O)O" or "CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure and properties:
Rule 1: If the molecule contains a bromine atom, it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). The presence of a bromine atom in a molecule often indicates that it has a high degree of reactivity, which could potentially lead to harmful interactions with other molecules or biological systems. However, this rule should be applied cautiously as there may be other factors that contribute to the toxicity of a molecule beyond the presence of a specific functional group or structural feature.
Rule 2: If the molecule contains a nitrogen atom bonded to a carbon atom through two single bonds instead of one double bond, it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This type of nitrogen atom is known as a primary amine, and it is often associated with increased reactivity and toxicity compared to other types of amines.
Rule 3: If the molecule contains a carbonyl group (a carbon-oxygen double bond) conjugated with another double bond, such as in the case of an enone or a dienone, it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Conjugated carbonyl groups can undergo nucleophilic addition reactions with other molecules, leading to the formation of toxic adducts or metabolites

================================

Rule 1: If a compound contains a benzene ring or any other aromatic system, it may have potential side effects on the human body due to its high reactivity towards biological systems. Therefore, compounds containing such structures should be avoided in drug design unless they are essential for the desired therapeutic action.
Rule 2: Compounds containing functional groups like aldehydes, ketones, carboxylic acids, esters etc. may exhibit toxic effects if present in excess amounts. These groups can interact with proteins and enzymes leading to disruption of normal cellular processes. Hence, these groups need to be carefully evaluated during drug development process.
Rule 3: The presence of charged ions like calcium, silver, chloride, thallium etc. in a compound indicates that it has a higher likelihood of being reactive and potentially harmful to living organisms. Such compounds should be thoroughly tested before being used as drugs.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure and properties:
Rule 1: If the molecule contains a negatively charged oxygen atom bonded to at least one carbon atom, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to the first SMILES string labeled as 1.
Rule 2: If the molecule contains a nitro group (-NO2) or a halogen atom such as bromine (Br) attached to a benzene ring, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to the second and third SMILES strings labeled as 1.
Rule 3: If the molecule contains a nitrogen-containing heterocyclic ring such as pyrazole or imidazole, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to the fourth SMILES string labeled as 1.
It's important to note that these rules are just suggestions and should be used carefully as they are based solely on the provided dataset and may not apply to all molecules. It's always best to consult with a qualified chemist before making any conclusions about the safety of a particular compound.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains the substructure "CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O" or "C(CC(=O)O)CO" then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule was derived from the first two SMILES strings which contain these substructures and were labeled as having adverse effects.
Rule 2: If the molecule contains the substructure "CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl" then it may not have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule was derived from the third SMILES string which does not contain any of the previously mentioned substructures but still has no reported adverse effects.
Rule 3: If the molecule contains the substructure "CC1(C(N2C(S1)C(C2=O)NC(=O)C

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a nitro group (-NO2) attached to an aromatic ring, then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules represented by SMILES strings labeled as "1" in the dataset.
Rule 2: If the molecule contains a coumarin moiety (represented by the SMARTS pattern "c1ccc2cc(oc1=O)cc2"), then it may not have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules represented by SMILES strings labeled as "0" in the dataset.
Rule 3: If the molecule contains both a nitro group (-NO2) attached to an aromatic ring and a coumarin moiety, then it may or may not have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps) depending on other structural features of the molecule. This rule applies to molecules represented by SMILES strings labeled as either "1" or "0" in the dataset.

================================

Rule 1: If there is a presence of C[C@H]1/C=C/C=C(\C(=O)NC\2=C(C3=C(C(=C4C(=C3C(=O)/C2=C/NN5CCN(CC5)C6CCCC6)C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C in the SMILES string, then it may be associated with neoplasm activity.
Rule 2: If there is a presence of CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO or CCCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-] in the SMILES string, then it may not be associated with neoplasm activity.
Rule 3: If there is a presence of CC(CC1=CC=C(C=C1)O)(C(=O)O)N or CCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O or CC(CC1=CC=C(C=C1)O)(C(=O)O)N or COC(=O)C(ccc1ccccc1)ncc2

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps):
Rule 1: If the molecule contains the substructure "CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3" then it is likely to have side-effect activity related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies only to the first SMILES string provided in the dataset.
Rule 2: If the molecule contains the substructure "C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl" then it is unlikely to have side-effect activity related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies only to the second SMILES string provided in the dataset.
Rule 3: If the molecule contains the substructure "C(C1C(C(C(C(O1)O)F)O)O)O" or "C(CC(C(=O)O)N)CN=C(N)N" or "C1=CN(C(=O)N=C1N)C

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps):
Rule 1: If the molecule contains the substructure "CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl" or "CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C" then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). These substructures contain the nitrogenous base cytosine which is known to have anti-neoplastic properties. However, further analysis would be required to confirm this hypothesis.
Rule 2: If the molecule contains the substructure "C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F" then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This substructure contains the fluorinated organic compound hexafluoropropene which is commonly used as a refrigerant and solvent but has also been shown to have anti-cancer properties. Further analysis would be required to determine its specific mechanism of action.
Rule 3: If the molecule contains the substructure "CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C" or "CCCCCCCCCCCCCCCOS(=O)(=O)O" or "CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N

================================

Rule 1: The presence of fluorine atoms in a compound increases its potential for causing adverse effects on health. This rule applies to molecules labeled as "1" in the given dataset. Fluorine is a highly electronegative element that can alter the electronic structure and reactivity of a molecule, leading to changes in its biological activity. For example, the molecule C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F contains two fluorine atoms and has been shown to have anti-cancer activity against various types of cancer cells. On the other hand, compounds without any fluorine atoms or with only one fluorine atom may be less likely to exhibit such activities.
Rule 2: A compound containing a sulfhydryl group (-SH) attached to an aromatic ring is more likely to cause adverse effects than those without this functional group. This rule applies to molecules labeled as "1" in the given dataset. Sulfhydryl groups can interact with other molecules through covalent bonds, which can lead to the formation of disulfide bridges or other types of chemical reactions. These interactions can affect the function of proteins and enzymes, potentially leading to toxic effects. For instance, the molecule CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a similar functional group, it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). The presence of this group indicates that the molecule may interfere with the body's normal functioning of carbonic anhydrase enzymes, which are involved in regulating pH levels within cells. This interference can lead to changes in cell growth and division, which can contribute to the development of cancer.
Rule 2: If the molecule contains a nitro group (-NO2) attached to an aromatic ring, it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Nitro groups are known to be highly reactive and can interact with other molecules in the body, leading to cellular damage and inflammation. These types of reactions can contribute to the development of cancer by causing mutations in DNA and promoting the growth of abnormal cells.
Rule 3: If the molecule contains a halogen atom such as chlorine (Cl) or fluorine (F), it may also have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). Halogen atoms can alter the chemical properties of a molecule

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps):
Rule 1: If the molecule contains the substructure "CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl" or "CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C" then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). These substructures contain the nitrogenous base cytosine which is known to have anti-neoplastic properties. However, further analysis would be required to confirm this hypothesis.
Rule 2: If the molecule contains the substructure "C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F" then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This substructure contains the fluorinated organic compound hexafluoropropene which is commonly used as a refrigerant and solvent but has also been shown to have anti-cancer properties. Further analysis would be required to determine its specific mechanism of action.
Rule 3: If the molecule contains the substructure "CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C" or "CCCCCCCCCCCCCCCOS(=O)(=O)O" or "CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a carbonyl group (C=O), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules #7, #8, #9, #10, #11, #12, #13, #14, #15, #16, #17, #18, #19, #20, #21, #22, #23, #24, #25, #26, #27, #28, #29, #30, #31, #32, #33, #34, #35, #36, #37, #38, #39, #40, #41, #42, #43, #44, #45, #46, #47, #48, #49, #50

================================

Rule 1: The presence of certain functional groups in a molecule may indicate its potential for causing adverse effects. For example, the presence of a carbonyl group (C=O) or a cyano group (CN) in a compound may increase its likelihood of being toxic. Therefore, analyzing the chemical structure of a molecule can provide valuable insights into its potential toxicity.
Rule 2: The size and shape of a molecule can also play a role in determining its ability to interact with biological systems. Large molecules with complex structures may be more likely to exhibit adverse effects than smaller, simpler compounds. Therefore, considering the molecular weight and complexity of a substance can help predict its potential toxicity.
Rule 3: The stereochemical configuration of a molecule can affect its reactivity and biological activity. For instance, enantiomers (mirror-image isomers) often have different physical and biological properties due to their distinct three-dimensional arrangements. Therefore, examining the stereochemistry of a compound can provide additional information about its potential toxicity.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a benzene ring with a sulfonamide substituent (-SO2NH2), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to neoplasms benign, malignant and unspecified (incl cysts and polyps) based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a carbonyl group (-C=O), then it may have the potential to cause adverse effects related to neoplasms benign, malignant and unspecified (incl cysts and polyps). This rule applies to molecules represented by SMILES strings CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)[O-])C, C1=NC2=C(N1COCCO)NC(=NC2=O)N, CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2, COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F, CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O.Cl, CCS(=O)(=O)C1=CC=C(C=C1)N, NCC

================================

